| Literature DB >> 4075317 |
R Ohno, K Kimura, I Amaki, Y Imamura, T Masaoka, T Miyazaki, Y Yoshida, Y Miura, T Maekawa, M Oguro.
Abstract
A phase II study of recombinant human leukocyte A interferon was conducted in 64 patients with multiple myeloma in a multi-institutional cooperative trial. Partial remission was achieved in ten (21.3%) of 47 evaluable patients and minor response was observed in five (10.6%). Side effects were noted in more than two-thirds of the patients. They included fever (58%), malaise (20%), anorexia (52%), nausea and vomiting (26%), lethargy (2%), and myelosuppression (56%). An antibody to recombinant human leukocyte A interferon was detected in one of 20 patients.Entities:
Mesh：
Substances：
Year: 1985 PMID： 4075317
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960